Literature DB >> 33517536

Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report.

Saba Naghavi1, Ahmad Pourmohammadi1, Iman Adibi2,3.   

Abstract

Protein S deficiency is a thrombophilia associated with an increased risk of thromboembolism. Previous studies have shown its role as a predisposing factor for venous thromboembolism, but its role in recurrent arterial ischemic stroke remains uncertain. Here we report a patient with recurrent ischemic stroke due to protein S deficiency. Oral anticoagulant treatment with vitamin K antagonist (VKA) drugs is used to treat and prevent thromboembolic events caused by thrombophilia, but it has many limitations, especially in the case of recurrent thromboembolic events. Direct oral anticoagulants (DOACs) have many advantages over VKA. Previous studies have shown that they are safe in cases of thrombophilia, but they are not well studied in recurrent ischemic stroke due to protein S deficiency. In this study our patient was treated with rivaroxaban. Protein S deficiency may be a predisposing factor in recurrent ischemic stroke, and rivaroxaban can be a safe and effective treatment option. Further studies are needed to confirm our findings.

Entities:  

Keywords:  Arterial thrombosis; Case report; Protein S deficiency; Rivaroxaban

Year:  2021        PMID: 33517536     DOI: 10.1007/s40120-021-00232-9

Source DB:  PubMed          Journal:  Neurol Ther        ISSN: 2193-6536


  4 in total

Review 1.  The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.

Authors:  Meyer Michel Samama
Journal:  Thromb Res       Date:  2010-10-02       Impact factor: 3.944

2.  Ischemic Stroke with Protein S Deficiency Treated by Apixaban.

Authors:  Ikkei Ohashi; Shinichi Wada; Fumitaka Yoshino; Takahiro Kuwashiro; Shinya Matsumoto; Taeko Hotta; Dongchong Kang; Yasushi Okada; Shun Shimohama; Masahiro Yasaka
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-01-13       Impact factor: 2.136

3.  Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.

Authors:  Angela Mirela Soare; Constantin Popa
Journal:  J Med Life       Date:  2010 Oct-Dec

4.  Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.

Authors:  Yana Vinogradova; Carol Coupland; Trevor Hill; Julia Hippisley-Cox
Journal:  BMJ       Date:  2018-07-04
  4 in total
  1 in total

Review 1.  Protein S: function, regulation, and clinical perspectives.

Authors:  Rinku Majumder; Tina Nguyen
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.